Loading your page…
Clinical, cosmetic and investigational dermatology
By Yang L, Mo W, Wang G and 1 others.
To identify psoriasis-associated candidate genes and regulatory features via integrated transcriptomic, immune and genetic analyses, and validate them in an imiquimod-induced psoriasis-like murine model.
Ward brings these articles into the same app as your cards and questions. One free account for Ward, Suture, Osler and Prognia.
Public GEO transcriptomic datasets were integrated after batch-effect correction. We performed differential expression, WGCNA, machine-learning-based feature selection and diagnostic modelling, CIBERSORT immune infiltration estimation, transcription-factor regulation, drug enrichment, colocalization and SMR analyses. In-vivo histological and Western blot validation was conducted in mice.
We obtained 767 candidate genes enriched in cell-cycle and immune-inflammatory pathways. The Lasso-XGBoost model (AUC = 0.923) yielded 11 candidate genes that well separate psoriasis patients from healthy controls. Drug enrichment identified Lucanthone. SMR revealed consistent expression-genetic directionality for LYN and IL1RN. Notably, the 11 machine-learning-derived signature genes mainly mark psoriasis disease activity and differ from the SMR-identified genetically supported causal genes LYN and IL1RN. Increased CDC20, CCNB1 and CDK1 protein levels were confirmed in mouse lesional skin.
This study suggests that CDC20 may serve as a potential biomarker for cell cycle and immune-inflammatory processes in psoriasis, providing a basis for further mechanistic and translational studies.
Published in Clinical, cosmetic and investigational dermatology. The abstract is shown as published and remains the work of its authors; read the full article at the source.
Prognia lists this article for reference and education. It is not medical advice. Always read the original and follow current guidelines and local protocols before acting on it.
